HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Health OTC Drugs Launches

Infirst Launches GSL Version Of Flarin Lipid Ibuprofen In UK

Executive Summary

Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand. 

You may also be interested in...



EU Business Round-Up: Mayoly Spindler Acquires Biohealth, Flarin Gets Funding, Karo Ready For M&A

The latest European consumer health business news: France's Mayoly Spindler acquires Italian supplements specialist Biohealth; UK-based Flarin gets funding to expand at home and abroad; and Sweden's Karo plots further M&A in 2021.

Infirst’s Flarin Lipid Ibuprofen Trialled As COVID-19 Treatment

A clinical trial will explore the effectiveness of OTC ibuprofen drug Flarin in reducing COVID-19 related respiratory failure in hospitalized patients, following "compelling" pre-clinical data.

David Vs Goliath – Flarin’s Macmillen On Slugging It Out With The Heavyweights

HBW Insight Exclusive: Flarin boss Andrew Macmillen on competing with the big OTC incumbents as a lean, innovation-focused company.

Table

View full table

Topics

Tags:
Health OTC Drugs Launches
UsernamePublicRestriction

Register

RS150237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By